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Mutations of nucleophosmin 1 are frequently found in acute myeloid leukemia and lead to aberrant cytoplasmic
accumulation of nucleophosmin protein. Immunohistochemical staining is therefore recommended as the tech-
nique of choice in front-line screening. In this study, we assessed the sensitivity and specificity of immunohisto-
chemistry on formalin-fixed bone marrow biopsies compared with gold standard molecular analysis to predict
nucleophosmin 1 mutation status in 119 patients with acute myeloid leukemia. Discrepant cases were further
characterized by gene expression analyses and fluorescence in situ hybridization. A large overlap between both
methods was observed. Nevertheless, nine patients demonstrated discordant results at initial screening. Five cases
demonstrated nuclear staining of nucleophosmin 1 by immunohistochemistry, but a nucleophosmin 1 mutation
by molecular analysis. In two cases this could be attributed to technical issues and in three cases minor subpopu-
lations of myeloblasts had not been discovered initially. All tested cases exhibited the characteristic nucleophos-
min-mutated gene expression pattern. Four cases had cytoplasmic nucleophosmin 1 staining and a nucleophos-
min-mutated gene expression pattern without a detectable nucleophosmin 1 mutation. In two of these cases we
found the chromosomal translocation t(3;5)(q25;q35) encoding the NPM-MLF1 fusion protein. In the other dis-
crepant cases the aberrant cytoplasmic nucleophosmin staining and gene expression could not be explained. In
total six patients (5%) had true discordant results between immunohistochemistry and mutation analysis. We con-
clude that cytoplasmic nucleophosmin localization is not always caused by a conventional nucleophosmin 1 muta-
tion and that in the screening for nucleophosmin 1 abnormalities, most information will be obtained by combining
immunohistochemistry with molecular analysis.
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ABSTRACT
Introduction 
Mutations in the nucleophosmin gene (NPM1) are found in
30% of patients with acute myeloid leukemia (AML) and lead
to aberrant accumulation of nucleophosmin protein in the
cytoplasm.1 Distinctive biological and clinical features can be
observed in NPM1-mutated AML, including a unique gene
expression profile, a distinct microRNA signature, low
expression of CD34 in more than 95% of cases, an increased
incidence of FLT3 internal tandem duplications (ITD) in about
40% of cases, and a good response to induction chemothera-
py.2-5NPM1-mutated AML was included as a provisional enti-
ty in the 2008 World Health Organization classification of
myeloid neoplasms.6
Currently more than 40 different mutations in the NPM1
gene have been identified.4 All these variants lead to common
changes at the C-terminus of the gene and cause aberrant dis-
location of the NPM1 protein into the cytoplasm of AML
blast cells. This feature of NPM1-mutated AML can be used
for diagnostic purposes. Indeed, immunohistochemical stain-
ing of NPM1 on bone marrow biopsies has been described to
be fully predictive of NPM1 mutations by two independent
research groups.1,7,8 The low costs and relative simplicity are
important advantages of immunohistochemistry in diagnos-
tic screening, especially if more sophisticated molecular tech-
niques are not available. On the other hand, compared to
molecular analyses, immunohistochemistry is more prone to
inter-observer variability and variability due to technical
issues. Indeed, in the study by Konoplev et al.9 immunohisto-
chemical staining was not completely predictive for NPM1
mutations. Still, immunohistochemical staining is recom-
mended as the technique of choice in simple front-line
screening, with a reported sensitivity and specificity of 100%
on B5-fixed and EDTA-decalcified bone marrow biopsies,
and for the diagnosis of AML patients presenting with a “dry
tap” or myeloid sarcoma.10,11
In this study, we assessed the sensitivity and specificity of
immunohistochemistry on formalin-fixed bone marrow
biopsies compared with gold standard molecular analysis
to predict NPM1mutation status in a large cohort of AML
patients from our institution. The cases that were found to
have a discrepancy between the two methods were exten-
sively evaluated.
Methods
Patients
Bone marrow biopsies for immunohistochemical analysis and
either peripheral blood or bone marrow aspirates for RNA isola-
tion were obtained from untreated patients diagnosed with AML
after obtaining informed consent. The study protocol was
approved by the Medical Ethical Committee of the University
Medical Center in Groningen.
Immunohistochemical staining for NPM1
The immunohistochemical stains were performed on bone mar-
row biopsies that were fixed in 10% neutral phosphate-buffered
formalin (3.6% formaldehyde) for at least 12 h, and decalcified in
a solution containing 10% (v/v) acetic acid and 10% formalin (v/v;
3.6% formaldehyde) for 1 or 2 days. Detection of NPM1 localiza-
tion was routinely performed on paraffin-embedded 3 μm (and
also 1-2 μm for discrepant cases) tissue sections by immunohisto-
chemical staining using a Benchmark XT immunostainer (Ventana
Medical Systems S.A., Tucson, AZ, USA). The NPM1 antigen was
retrieved with TRIS EDTA buffer (pH 8.5). Endogenous peroxi-
dase was blocked with H2O2. Slides were incubated with 1:50
diluted supernatant of the anti-NPM1 antibody (clone 376, 1G3)
(kindly provided by Prof. Falini, Perugia, Italy). NPM1 was visual-
ized using an ultraview universal DAB detection kit (Ventana).
The nucleolin antigen was retrieved with a TRIS EDTA buffer (pH
9.0). Anti-nucleolin  antibody (C23, Santa Cruz, Dallas, TX, USA)
was used at a dilution of 1:50 and visualized using horse-radish
peroxidase-labeled rabbit-anti-mouse and goat-anti-rabbit anti-
bodies (Dako, Copenhagen, Denmark) and 3,3′-diaminobenzidine
(Sigma Aldrich, St Louis, MO, USA). The NPM1 and nucleolin
stains were initially scored as being either exclusively nuclear or
combined nuclear and cytoplasmic by an experienced
hematopathologist (SR, AD or PMK).
Molecular analysis of NPM1
Molecular NPM1 mutation analysis was performed using
reverse transcriptase polymerase chain reaction (RT-PCR) of exon-
12 harboring most NPM1 mutations.4 cDNA fragment analysis
was performed with a fluorescent-labeled forward primer (CTTC-
CGGATGACTGACCAAGAG) and a reverse primer (CCTGGA-
CAACATTTATCAAACACG). The fragment analysis was vali-
dated by sequencing the RT-PCR product for the first 100 patients’
samples analyzed with fragment analysis, revealing 100% accura-
cy for detecting either two wild-type alleles (non-mutated NPM1)
or a wild-type and mutated allele (NPM1-mutated). For the cases
with cytoplasmic NPM1 staining but no mutation by fragment
analysis, a further analysis of exons 9 and 11 was performed by
RT-PCR using the forward primer AGCGCCAGTGAAGAAATC
and the reverse primer CACGGTAGGGAAAGTTCTC and
sequencing the PCR product.
Quantitative real-time polymerase chain reaction analyses
Total RNA was isolated using an RNeasy kit from Qiagen
(Venlo, The Netherlands) according to the manufacturer’s recom-
mendations. The presence of NUP98/NSD1 and the reciprocal
NSD1/NUP98 translocations was determined by quantitative RT-
PCR. Primer sequences and cycle conditions have been described
previously.12 Samples known to express the NUP98/NSD1 and the
reciprocal NSD1/NUP98 translocations were kindly provided by
Dr. PJM Valk (Erasmus MC, Rotterdam, The Netherlands) and
used as positive controls.
The sequences of the primers used for the quantitative RT-PCR
analysis of various HOX genes, MEIS1, PBX3, BAALC and MN1
and the housekeeping genes RPL27 and HPRT are presented in
Online Supplementary Table S1. All quantitative RT-PCR analyses
were performed in triplicate and the mean expression of these
triplicate analyses is indicated in the results.
Fluorescence in situ hybridization
Cytogenetic and fluorescence in situ hybridization (FISH) studies
were performed according to standard methods. All discrepant
samples were screened for the t(3;5) NPM-MLF1 gene fusion using
FISH. Both interphase nuclei and metaphases were analyzed with
the TLX3 Breakapart probe (CytoCell, LPH050, Cambridge, UK)
and with the bacterial artificial chromosome (BAC) (RP11-117L6
chr:170,746,923 - 170,922,033), kindly provided by Prof M. Rocchi
(Department of Genetics and Microbiology, University of Bari,
Italy) to confirm the presence of a break within the NPM1 gene
suggestive of a translocation t(3;5).13,14
Results
No complete concordance for immunohistochemical
analysis on formalin-fixed bone marrow biopsies 
and molecular analysis for the detection 
of NPM1 mutations
Both immunohistochemical and RT-PCR analyses for
NPM1 mutations were performed in a total of 119 patients
diagnosed with AML between 2005 and 2010 in the
University Medical Center Groningen. Patients with a
t(8;21), t(15;17), inv(16) or t(16;16) were excluded, since
NPM1 mutations have been reported to be mutually
exclusive with these cytogenetic abnormalities.1,5 The
patients’ characteristics are shown in Table 1.
Screening for NPM1 mutations by fragment analysis
revealed mutated NPM1 in 34 out of the 119 patients
(29%). In the subgroup of patients with normal karyotype
AML (n=68), 28 (41%) had an NPM1 mutation by frag-
ment analysis. Screening for NPM1 dislocation by
immunohistochemistry on formalin-fixed bone marrow
biopsies revealed cytoplasmic NPM1 in 33 out of the 119
patients (28%). However, five cases had mutant NPM1 by
fragment analysis but did not have characteristic cytoplas-
Immunohistochemical and molecular analysis of NPM1 mutations
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Table 1. Patients’ characteristics.
Age(years) 
Mean                                                                   57
Range                                                               17-81
Sex
Female                                                              52%
Cytogenetic characteristics
Normal karyotype                                            68                              57%
Unfavorable                                                      28                              24%
Other                                                                  23                              19%
FLT3mutation status
FLT3 wt                                                               92                              77%
FLT3-ITD                                                            27                              23%
wt: wild type; ITD: internal tandem duplication.
mic localization of NPM1 according to the initial immuno-
histochemistry studies used for diagnosis; conversely, in
four cases, no NPM1 mutation was detected by fragment
analysis although immunohistochemistry showed cyto-
plasmic localization of NPM1 (Figure 1, Online
Supplementary Figure S1, Table 2). 
All cases with discordant results were analyzed in more
depth. Since mutations of exons 9 and 11 of the NPM1
gene have been described to occur in rare cases,15,16 we per-
formed additional sequencing analysis of exons 9, 11 and
12 for those four AML cases exhibiting cytoplasmic NPM1
by immunohistochemistry but no mutation by fragment
analysis. This analysis did not reveal any mutations.
Recently, a patient was reported with mutated NPM1
detected by molecular analysis but predominant nuclear
NPM1 by immunohistochemistry with faint localization
in the cytoplasm.17 It was suggested that the amino acids
at position 270 and 272 could be important for proper sub-
cellular localization of NPM1. The types of NPM1 muta-
tions found in our discrepant cases are shown in Online
Supplementary Table S2. All these mutations were found in
exon 12 of the NPM1 gene and did not resemble the muta-
tion described by Pianta and colleagues.
Further analysis of the five discrepant cases included re-
cutting tissue sections at 1-2 µm and microscopic analysis
at 100x magnification. In two discordant cases with a
proven mutation, blast cells again showed exclusively
nuclear staining (cases 1 and 4 in Table 2; Figure 1 and
Online Supplementary Figure S1). In one case of AML with
signs of differentiation (FAB M2), a minority of cells, prob-
ably the blasts, showed cytoplasmic staining (case 3),
which had been overlooked in the original analysis of the
thicker tissue sections. In an additional case with AML
with multilineage dysplasia, previously classified as AML
M6 (case 2), only small clusters of myeloblasts showed
cytoplasmic staining. Finally as regards the fifth discrepant
case, a patient with unclassifiable AML (dry tap due to
extensive sclerosis) and very few circulating blasts, the
biopsy used for the original analysis showed only nuclear
staining. However, a biopsy taken one day earlier in the
referring hospital, and only analyzed at the re-assessment,
convincingly showed cytoplasmic staining in apparently
more blastic cells with larger nuclei and bigger nucleoli
(case 5, Online Supplementary Figure S1). Altogether, after
re-analysis using 1-2 µm sections of the five discrepant
cases with detectable mutations of NPM1 without cyto-
plasmic staining, only two cases remained discrepant.
In the group of four discordant cases with cytoplasmic
staining of NPM1 but no detectable mutation (cases 6-9 in
Table 2), cytoplasmic staining was very strong in one case
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Figure 1. Immunohistochemistry
for NPM1. Representative exam-
ples of immunohistochemical
staining of AML cases are shown.
(A) A case with strict nuclear stain-
ing of NPM1 and wild-type NPM1
by fragment analysis; (B) a case
with nuclear and cytoplasmic stain-
ing of NPM1 and an NPM1 muta-
tion by fragment analysis; (C) a dis-
crepant case (case 1, Table 2) with
strict nuclear staining but an NPM1
mutation found by fragment analy-
sis; (D) a discrepant case (case 2,
Table 2) with a minor population of
blasts with combined nuclear and
cytoplasmic staining (black arrows)
and many other cells with exclu-
sively nuclear staining (orange
arrows). The blasts with cytoplas-
mic expression had been over-
looked at the initial screening; (E) a
discrepant case (case 6, Table 2)
with both nuclear and very strong
cytoplasmic staining but no NPM1
mutation found by molecular analy-
sis; (F) a discrepant case (case 8,
Table 2) with nuclear and cytoplas-
mic staining with a
t(3;5)(q23;q3?3) likely involving
NPM1. The inserts for cases 6 (E)
and 8 (F) show exclusively nuclear
staining for the nucleolin protein as
detected with the C23 antibody. All
photographs were taken with a
100x oil immersion lens. 
A B
C D
E F
(case 6) and fuzzy to granular in cases 8 and 9, whereas
cytoplasmic staining of a very limited population of blasts
was observed in case 7 (Figure 1). Immunohistochemistry
studies for nucleolin were performed to exclude artifacts,
i.e. abnormal general diffusion of nuclear proteins into the
cytoplasm leading to false positive immunohistochemical
results. Such artifacts were not observed (Figure 1).
To analyze the impact of the staining technique, all dis-
crepant cases were re-analyzed using APAAP in the visu-
alization of NPM1 in immunohistochemistry. The results
are shown in Online Supplementary Figure S1 and were in
accordance with the results obtained by DAB visualiza-
tion. After re-analysis of the four discrepant cases with
cytoplasmic staining of NPM1 without detectable muta-
tion all these cases remained discrepant.
Cases of acute myeloid leukemia with discordant
immunohistochemical and molecular results of NPM1
mutation analyses have high expression of HOXA
and HOXB genes 
Patients with NPM1-mutated AML are considered a
specific subgroup based on distinct clinical as well as bio-
logical characteristics.1,4,5,18-20 One of these features is a spe-
cific gene expression profile, characterized by strongly
increased expression of HOX genes from both the A and
B cluster, MEIS1 and PBX3 and down-regulation of CD34
compared to the expression of these genes in AML sam-
ples with wild-type NPM1.2,5,21 The (re)activation of a
stem cell-like HOX gene signature in NPM1-mutated
AML has been hypothesized to contribute to the
leukemic transformation. We wondered whether the dis-
cordant AML cases had a specific expression profile for
these genes and performed quantitative RT-PCR studies
for the expression of several HOXA/HOXB genes, MEIS1,
PBX3, BAALC and MN1. The tested cases (1-4 from Table
2) with nuclear staining of NPM1 by immunohistochem-
istry but an NPM1 mutation by fragment analysis
showed the gene expression profile expected for NPM1-
mutated AML (Figure 2), suggesting that these cases were
true false negative cases as assessed by immunohisto-
chemistry. More interestingly, the gene expression pat-
terns of three out of the four AML cases with cytoplasmic
NPM1 by immunohistochemistry but no detectable
NPM1 mutation by fragment analysis also closely resem-
bled those of NPM1-mutated AML with high HOXA,
HOXB and MEIS1 mRNA expression (Figure 2). The
fourth case (case 7 in Table 2) demonstrated high expres-
sion of the HOXA genes and MEIS1, but low expression
of HOXB5. Since the latter gene expression pattern is fre-
quently observed in AML with MLL translocations,22 we
used FISH to test for abnormalities of chromosome 11
(q23.1) but these were not detected. Recently, Hollink et
al.12 described a group of AML with NUP98/NSD1
translocations and a HOX gene expression pattern resem-
bling the gene expression pattern of NPM1-mutated
cases. We screened all discordant patients, including
those with high HOXA and HOXB expression, for
NUP98/NSD1 by a specific RT-PCR. This revealed no
NUP98/NSD1 expression in these cases.
NPM-MLF1 gene fusion detected in two out 
of four discrepant cases with cytoplasmic NPM1 
but no detectable NPM1 mutation
Our analysis so far identified four AML cases (cases 6-9
in Table 2) with cytoplasmic NPM1 staining by immuno-
histochemistry, in the absence of an NPM1 mutation
detected by molecular analysis. It has been described that
cytoplasmic NPM1 staining can be observed in cases with-
out a conventional NPM1mutation, but in the presence of
the rare chromosomal translocation t(3;5)(q25;q35).23 This
translocation generates the chimeric gene named NPM-
myelodysplasia/myeloid leukemia factor 1 (NPM-MLF1)
encoding the NPM-MLF1 fusion protein.24 The mechanism
explaining the cytoplasmic NPM1 dislocation in these
cases remains to be clarified. We tested the discrepant
cases in our study demonstrating cytoplasmic NPM1
staining, but no NPM1 mutation for the NPM-MLF1 gene
translocation by FISH using the RP11-117L6 and the TLX3
Break apart probe. This analysis revealed the presence of
a break within the NPM1 gene highly suggestive of an
NPM-MLF1 gene translocation in two out of four dis-
crepant cases (cases 8 and 9 in Table 2, Figure 3). 
Immunohistochemical and molecular analysis of NPM1 mutations
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Table 2. Characteristics of the AML cases for which immunohistochemistry and fragment analysis for the detection of NPM1 mutations gave dis-
crepant results.
N. FA Initial IHC Revised IHC Age Karyotype FLT3 WBC FAB WHO
1 mut nuc nuc 71 NK ITD 23 M1 AML without maturation
2 mut nuc hetero* 70 +8 ITD 5 M6 AML with multilineage dysplasia
3 mut nuc hetero* 53 NK wt 6 M2 AML with maturation
4 mut nuc nuc 64 NK wt 5 dry tap dry tap
5 mut nuc hetero** 41 NK ITD 3 dry tap dry tap
6 wt nuc+cyt nuc+cyt 64 NK wt 13 M6 AML with multilineage dysplasia
7 wt nuc+cyt nuc+cyt 52 del 8p,del 9q,add 16p wt 47 M5 therapy related AML
8 wt nuc+cyt nuc+cyt 60 t(3;5)(q23;q3?3), +8 ITD 190 M2 AML with maturation
9 wt nuc+cyt nuc+cyt 45 t(3;5)(q23;q3?3), +8 wt 66 M5 AML with multilineage dysplasia
FA: fragment analysis; mut: mutated; wt: wild-type; IHC: immunohistochemistry; nuc: nuclear staining; cyt: cytoplasmic staining; hetero: heterogeneous staining pattern; ITD: inter-
nal tandem duplication; WBC: white blood cell count (x109/L); FAB:  French-American-British classification; WHO: World Health Organization classification of myeloid neo-
plasms; NK: normal karyotype; D, no T: dead without treatment; D, D: died of progressive disease; D, TRM: treatment-related death; y, year. *Heterogeneous pattern with only small
clusters of myeloblasts showing cytoplasmic staining; **Heterogeneous pattern with first biopsy showing nuclear and cytoplasmic staining, but a second biopsy showing only
nuclear staining.
Discussion
The aim of this study was to evaluate the value of
immunohistochemistry on formalin-fixed bone marrow
biopsies and molecular analysis for the detection of NPM1
mutations and further characterize the cases for which the
two techniques gave discrepant results. We observed a
high percentage of concordance between the two meth-
ods of mutation detection. Nevertheless, results were dis-
cordant in a small subgroup of patients (5% in the studied
cohort). 
To analyze the possible effects of inter-observer variabil-
ity in the use of immunohistochemistry, a cohort of 50
patients, including all cases that showed discordant results
by immunohistochemistry and fragment analysis, were
re-scored blindly and independently by three
hematopathologists and later discussed in a panel session.
All nine cases remained discrepant after this procedure
(data not shown).
Previously, Falini and colleagues reported that immuno-
histochemical analysis had 100% specificity and sensitivi-
ty for the detection of mutated NPM1.7 The superiority of
their results might be explained by a difference in fixation
technique, i.e. B5 fixation instead of formalin fixation. The
B5 fixation technique used for hematopoietic tissues is
well known for its superior morphological detail com-
pared to formalin fixation. However, this technique has
disadvantages, including difficulties with antigen retrieval
for some antibodies (e.g. CD30, cyclin D1) and limitations
to molecular studies. Moreover, the fixation can be prob-
lematic with respect to safety and disposal requirements
in the laboratory, since B5 contains mercuric chloride.
Consequently, most pathology laboratories currently use
purely formalin-based fixation techniques, which provide
a safe alternative.25 In view of these considerations, all
biopsies of the nine initially discordant cases were re-cut
for thinner tissue sections and re-analyzed at higher mag-
nification. Furthermore, an additional biopsy taken in the
referring hospital was included for re-analysis. In three of
the five cases with initially nuclear staining but proven
NPM1mutations and a gene expression pattern character-
istic of NPM1-mutated AML, we observed either a minor
C.M. Woolthuis et al.
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Figure 2. Gene expression of discrepant cases. Results of quantitative RT-PCR of HOX genes, MEIS1, PBX3, BAALC and MN1 for the AML cases
with discrepant finding between immunohistochemistry and fragment analysis for the detection of NPM1 mutations. The graphs shows rela-
tive mRNA expression of the indicated genes compared to the mean expression of the housekeeping genes RPL27 and HPRT. The first eight
bars from left to right in each graph represent the data from cases 1-4 and 6-9 according to Table 2.
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subpopulation with cytoplasmic staining or a discordance
between two subsequent biopsies (Table 2). Only in two
cases did the blasts again show exclusively nuclear NPM1
staining. This suggests that fixation and histotechnical fac-
tors may indeed contribute to the generation of false neg-
ative staining results. Differences in fixation, decalcifica-
tion and staining procedures, leading to difficulties in
microscopic evaluation, have also been addressed in previ-
ously published studies.1,7-9,11 However, additional studies
directly comparing different fixation techniques are neces-
sary to assess the relevance of the fixation technique. 
In addition to technical issues, characteristics of the AML
blasts might also be important. We observed false negative
results in a case of AML with myeloid maturation and one
with a large component of erythroblasts. The cytoplasmic
pattern of NPM1 is generally most prominent in
myeloblasts and monoblasts as well as early erythroblasts.
Indeed, cytoplasmic staining may be very weak or absent
in more mature cells and might be below detection levels
or more easily overlooked, especially in AML cases with
M5b morphology.26 Moreover, as is also illustrated by the
results of this study, in rare cases only a very small popula-
tion of blasts with cytoplasmic staining might be present.
The detection of mutant NPM1 could be improved by
applying an antibody specific for mutant NPM1. An
NPM1-mutant specific antibody has been generated for
use in western blot analysis.27 However, to the best of our
knowledge, no such antibody is available for immunohis-
tochemistry. Importantly, none of the cases with mutated
NPM1 without overt cytoplasmic staining demonstrated
the frameshift mutation, leading to a truncated protein, as
was described by Pianta et al.17 Nevertheless, the reported
truncated protein illustrates that not all identified NPM1
mutants are necessarily associated with overt cytoplasmic
localization of NPM1.
The four cases with cytoplasmic NPM1 without
detectable NPM1 mutation demonstrated the typical ele-
vated expression of HOX and MEIS1 genes, which has
been shown to be associated with NPM1-mutated AML,
suggesting that these cases do not reflect regular NPM1
germline AML. It could, therefore, be argued that
immunohistochemistry should be applied to identify
these rare, but interesting cases. Rare mutations in exons 9
and 11 of the NPM1 gene were excluded by sequencing.
In two out of the four discrepant cases, analysis of the
FISH results was highly suggestive of the rare chromoso-
mal translocation t(3;5)(q25;q35) encoding the NPM-MLF1
fusion protein. This finding is in line with that of a previ-
ous study describing aberrant cytoplasmic NPM1 localiza-
tion in AML cases carrying a t(3;5).23 In this study AML
with t(3;5) was reported to account for only 0.25% of all
AML in adults aged between 15 and 60 years old. In our
complete cohort of 119 cases, t(3;5) was found in 3% of all
analyzed cases. Two out of these four cases demonstrated
cytoplasmic NPM1. The exact breakpoints of the other
two cases were not analyzed in detail. It is currently
unknown how NPM-MLF1 results in cytoplasmic expres-
sion. Apparently, not only the presence of a new NES
motif in NPM1 is required to cause cytoplasmic disloca-
tion.  For two out of four cases we could not find an expla-
nation for the aberrant cytoplasmic NPM1 staining. This
staining does not seem to represent an artifact because it
could be reproduced; furthermore, one of the two cases
had a gene expression pattern compatible with NPM1-
mutated AML and the other demonstrated high expres-
sion of HOXA genes and MEIS1 (albeit with low HOXB5
Immunohistochemical and molecular analysis of NPM1 mutations
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Figure 3. FISH analysis for NPM-MLF1 translocation. On the left, results of metaphase FISH analysis of an AML case with a split in the TLX3
gene on chromosome 5q35. Spectrum red and green TLX3 breakapart probe (Cytocell, LPH, 050). On the right, metaphase FISH analysis of
an AML case with a split in the NPM1 gene on chromosome 5q35. Spectrum red NPM1 specific BAC (RP11-117L6) and spectrum green spe-
cific BAC (RP11-600N9; control on 5p15.33). The pictures show results of the FISH analysis of case 8 from Table 2.
expression). Thus, it is very possible that there is a small
subgroup of AML cases that present cytoplasmic NPM1
localization of (yet) unknown origin. Taken together these
data illustrate that, when screening for NPM1 abnormali-
ties, most information can be obtained by combining
immunohistochemistry with molecular analysis.
Therefore, if possible, both techniques should be per-
formed in parallel. Nevertheless, immunohistochemistry
for NPM1 could still represent a reasonable screening pro-
cedure for laboratories in developing countries that are not
equipped for molecular studies.
The terms NPM1-mutated and NPMc+ are often used
interchangeably. Our data and those of others9,23 suggest
that cytoplasmic NPM1 localization is not always caused
by a conventional NPM1 mutation, but can also be caused
by t(3;5)(q25;q35) and possibly by other abnormalities.
Moreover, cases with mutated NPM1 do not always show
overt cytoplasmic staining of NPM1 on formalin-fixed bone
marrow biopsies. Nevertheless, even when performed on
formalin-fixed bone marrow biopsies, immunohistochem-
istry has a high specificity and sensitivity for the detection
of mutated NPM1. In view of the occasional discrepant
results between immunohistochemistry and molecular
analysis, we would recommend that the routine detection
of NPM1 mutations in newly diagnosed AML patients
should optimally be based on both immunohistochemical
and molecular analyses. When immunohistochemical
methods on formalin-fixed bone marrow biopsies are used,
1-2  µm tissue sections are preferred. Further studies are
needed to elucidate the relevance of different factors that
might contribute to discordant results between immunohis-
tochemical and molecular analyses. In addition, the clinical
relevance of the discrepancies between immunohistochem-
ical and molecular detection of NPM1mutations will be an
important issue for further research. 
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